Successful Treatment of the TEMPI Syndrome with Pomalidomide Plus Dexamethasone Followed by Autologous Stem Cell Transplantation.
|
| Abstract |
TEMPI syndrome is a rare disease associated with plasma cell neoplasms. Although previous studies have reported that bortezomib is effective as a first-line treatment for TEMPI syndrome, some cases are refractory to this treatment. Pomalidomide, a kind of immunomodulatory drug, is widely used for the treatment of relapsed or refractory multiple myeloma and could be administered without dose modification in patients with renal dysfunction. We present a case of bortezomib-refractory TEMPI syndrome with renal insufficiency that was successfully treated with a combination of pomalidomide and low-dose dexamethasone with minimal adverse effects, followed by autologous hematopoietic stem cell transplantation (ASCT). To the best of our knowledge, this is the first case of TEMPI syndrome that was successfully treated with pomalidomide. Pomalidomide may be suitable for patients who do not respond to a proteasome inhibitor-based treatment. In addition, a subsequent ASCT could also be effective for achieving a further treatment response.
|
|---|---|
| Authors | Shunto Kawamura, Masaharu Tamaki, Yuhei Nakamura, Masakatsu Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Kazuki Yoshimura, Shimpei Matsumi, Ayumi Gomyo, Yosuke Okada, Yu Akahoshi, Machiko Kusuda, Kazuaki Kameda, Aki Tanihara, Shun-Ichi Kimura, Hideki Nakasone, Shinichi Kako, Yoshinobu Kanda |
| Journal | Acta haematologica (Acta Haematol) Vol. 145 Issue 5 Pg. 553-559 ( 2022) ISSN: 1421-9662 [Electronic] Switzerland |
| PMID | 35605591 (Publication Type: Case Reports) |
| Copyright | © 2022 S. Karger AG, Basel. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!